US Patent
US9808530 — Composition of tiacumicin compounds
Formulation · Assigned to Astellas Pharma Europe BV · Expires 2034-05-28 · 8y remaining
Vulnerability score
42/100
Strong — defensible against typical IPR challenges
What this patent protects
This patent protects a composition of tiacumicin compounds combined with specific excipients, such as xanthan gum or carrageenan, for use in a formulation.
USPTO Abstract
A composition comprising as the active ingredient one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a solvate thereof, in combination with an excipient, selected from the group consisting of a xanthan gum, carrageenan, sodium alginate, guar gum, water dispersible cellulose (microcrystalline cellulose and sodium carboxymethylcellulose) and mixtures thereof is provided. Further, use of an excipient, selected from the group consisting of a xanthan gum, carrageenan, sodium alginate, guar gum, water dispersible cellulose (microcrystalline cellulose and sodium carboxymethylcellulose) and mixtures thereof as an anti-foaming agent in a composition comprising as the active ingredient one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a solvate thereof is provided.
Drugs covered by this patent
- Dificid (FIDAXOMICIN) · Cubist Pharms Llc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.